Solid Biosciences LLC

Yahoo Finance • 10 days ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • last month

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of... Full story

Yahoo Finance • last month

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia – – FALCON Phase 1b clinical trial participant screening underw... Full story

Yahoo Finance • 2 months ago

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

- Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) - - AAV-SLB101 has been g... Full story

Yahoo Finance • 2 months ago

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines - - New Innovative Licensing and Access Pathway (ILAP) designation provides unique, end-to-end regulatory... Full story

Yahoo Finance • 3 months ago

Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion

Company Logo The Duchenne Muscular Dystrophy Drugs Market presents opportunities in advanced genetic therapies, digital health, and adaptive models amid rising global demand. Strategic alliances, resilient supply chains, and localized str... Full story

Yahoo Finance • 3 months ago

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

CHARLESTOWN, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INS... Full story

Yahoo Finance • 3 months ago

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

- Non-exclusive license for Solid’s proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio’s gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an upfront payment and is... Full story

Yahoo Finance • 4 months ago

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announce... Full story

Yahoo Finance • 5 months ago

Solid Biosciences’ SWOT analysis: promising DMD gene therapy stock faces pivotal year

Solid Biosciences Inc. (NASDAQ:SLDB) is entering a critical phase in its development of gene therapies for rare neuromuscular and cardiac diseases. The biotechnology company’s lead candidate, SGT-003 for Duchenne muscular dystrophy (DMD),... Full story

Yahoo Finance • 5 months ago

Sarepta Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of approximately $2 billion and... Full story

Yahoo Finance • 5 months ago

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 - - FA (SGT-212): Phase 1b trial initiation expected in Q4 20... Full story

Yahoo Finance • 5 months ago

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth consecutive day on Monday, jumping 10 percent to... Full story

Yahoo Finance • 5 months ago

Solid Biosciences' SWOT analysis: gene therapy stock poised for growth amid challenges

Solid Biosciences Inc. (NASDAQ:SLDB), with a market capitalization of $544 million, is a genetic medicine company at the forefront of developing innovative gene therapies for rare neuromuscular and cardiac diseases. With a primary focus o... Full story

Yahoo Finance • 5 months ago

Sarepta Therapeutics' SWOT analysis: stock faces challenges amid promising pipeline

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of $1.36 billion and a stock th... Full story

Yahoo Finance • 5 months ago

Solid Biosciences gets FDA fast track status for heart disease therapy

[Glass bottles in production in the tray of an automatic liquid dispenser, a line for filling medicines against bacteria and viruses, antibiotics and vaccines] aleksejplatonov/iStock via Getty Images * Solid Biosciences (NASDAQ:SLDB [ht... Full story

Yahoo Finance • 5 months ago

Solid Biosciences stock rating reiterated at Market Outperform by JMP

Investing.com - JMP Securities has reiterated its Market Outperform rating on Solid Biosciences (NASDAQ:SLDB) with a price target of $15.00. The stock has shown remarkable momentum, gaining nearly 97% over the past six months and about 1... Full story

Yahoo Finance • 6 months ago

Solid Biosciences' SWOT analysis: gene therapy stock shows promise amid challenges

Solid Biosciences Inc. (NASDAQ:SLDB), a genetic medicine company focused on developing gene therapies for neuromuscular and cardiac diseases, has been attracting significant attention from investors and analysts alike. According to Invest... Full story

Yahoo Finance • 6 months ago

Citi maintains Buy rating on Solid Biosciences stock amid Elevidys safety concerns

Investing.com - Citi has reiterated a Buy rating and $14.00 price target on Solid Biosciences (NASDAQ:SLDB) stock, which has surged over 70% in the past six months and currently trades at $5.58. The renewed rating comes following safety... Full story

Yahoo Finance • 6 months ago

Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT

Solid Biosciences Inc. (NASDAQ:SLDB) is one of the best stocks to invest in for a quick return.Solid Biosciences Inc. (NASDAQ:SLDB) Robotic arms performing diagnostic tests in a healthcare technology lab. Citi initiated coverage on Solid... Full story